TPE:6838

3 stories mentioning TPE:6838Updated 24d ago

Every FINWIRES story that references TPE:6838, newest first.

Formosa Pharmaceuticals, Samil Pharmaceutical Sign Drug Licensing Deal in Vietnam

Formosa Pharmaceuticals (TPE:6838) signed an exclusive licensing deal with South Korea's Samil Pharmaceutical (KRX:000520) for commercialization rights of its ophthalmic drug clobetasol propionate suspension (APP13007) in Vietnam.The agreement covers treatment for post-operative eye inflammation and pain, with financial terms including upfront payments, milestones and royalties, according to a Thursday Taiwan Exchange filing.Formosa said the Vietnam eye care market offers steady growth, and the deal is expected to support future sales and business development.Deal details, however, remain confidential.

KRX:000520TPE:6838

Asia33d ago

Formosa Pharmaceuticals Gets Taiwan's Health Ministry for Pain Relief Drug; Shares Rise 3%

Formosa Pharmaceuticals (TPE:6838) received approval from Taiwan's Ministry of Health and Welfare for a drug to treat inflammation and pain following ocular surgery, according to a Monday Taiwan Exchange filing.Shares gained about 3% in Tuesday's late morning trade.The drug dubbed APP13007, is marketed as BYQLOVI Ophthalmic Suspension 0.05%.Financial details and accumulated development costs were not disclosed.

TPE:6838

Asia33d ago

Formosa Pharmaceuticals' BYQLOVI Eye Drop Wins Taiwan Approval for Post-Surgery Pain Treatment

Taiwan's Ministry of Health and Welfare approved Formosa Pharmaceuticals' (TPE:6838) eye-drop BYQLOVI for post-surgery eye-pain treatment, according to a filing on Tuesday.The new drug, approved Tuesday, has a code of APP13007.

TPE:6838

Track with the FINWIRES app suite

FolioX

Track TPE:6838 in your portfolio

WheelAI

Analyze TPE:6838 options with the wheel strategy

StockInsider

See market sentiment on TPE:6838